Feature | May 16, 2013

Nearly 50 Percent of Patients With Cardiac Device Infections Don’t Survive Beyond Three Years

New study of Medicare patients presented at 2013 Heart Rhythm Society Meeting

May 16, 2013 — The incremental mortality in implantable pacemaker and defibrillator recipients who experience a device infection, compared to patients without device infection, is substantial and persists for at least three years after index hospitalization with infection. These are the key findings of a retrospective cohort study of 200,219 Medicare fee-for-service patients undergoing cardiac device procedures, with and without infection, that were presented today by M. Rizwan Sohail, M.D., a researcher from the Mayo Clinic divisions of infectious diseases and cardiovascular diseases, at Heart Rhythm 2013, the Heart Rhythm Society’s 34th Annual Scientific Sessions.

Previously, Sohail and his collaborators have reported that patients with cardiac device infections experience a two-fold increase in the mortality rate one year after device implantation, compared to patients without an infection. In this new study, Sohail and collaborators looked at the long-term mortality three years after the device procedure in 200,219 Medicare beneficiaries that underwent permanent pacemaker and defibrillator procedures between Jan. 1, 2007 and Dec. 31, 2007, including 5,817 patients with cardiac device infections.

Key findings of the study included:

  • The 15-29 percent higher mortality seen in patients with cardiac device infections, compared to patients without cardiac device infections, continued for at least three years.
  • Three years after the procedure:
    • Patients with pacemakers (PM) infection had 54 percent mortality, vs. 33 percent without PM infection (P<0.001)
    • Patients with ICD infection had 48 percent mortality vs. 32 percent without ICD infection (P<0.001)
    • Patients with CRT-D infections had a 51 percent mortality vs. 37 percent without CRT-D infection (p<0.001)
  • For PM patients with a device infection, the incremental mortality associated with device infection continues to increase for at least three years.

“It is well known that cardiac device therapies such as pacemakers, implanted cardioverter-defibrillators (ICDs), and cardiac resynchronization therapy/defibrillators (CRT-Ds) can reduce morbidity and mortality in appropriately selected patients,” said Sohail, “Unfortunately, these benefits can be significantly reduced, if the implantation/replacement procedure is complicated by a device infection. The focus of this study was to better understand the long-term mortality associated with CIED infections, stratified for different cardiac device types.”

This study was funded by Tyrx Inc., maker of implantable combination drug/device products focused on infection control for implantable electrophysiology devices.

For more information: www.HeartDeviceInfection.com

Related Content

caffeine consumption, extra heartbeats, UCSF study, UC San Francisco, Journal of the American Heart Association
News | EP Lab| February 04, 2016
Contrary to current clinical belief, regular caffeine consumption does not lead to extra heartbeats, which, while...
Stereotaxis, Philips, collaboration, Niobe ES remote magnetic navigation system, Allura Xper FD10 cardiovascular X-ray

Niobe ES image courtesy of Stereotaxis Inc.

Technology | Cath Lab| February 04, 2016
February 4, 2016 — Stereotaxis and Philips have signed an addendum pursuant to their existing Development and Coopera
Biotronik, CE approval, Ilivia ICDs and CRT-Ds, ProMRI, MRI AutoDetect
News | Implantable Cardioverter Defibrillators (ICD)| February 03, 2016
Biotronik announced CE approval for its new Ilivia implantable cardioverter defibrillators (ICDs) and cardiac...
Abbott, Kalila Medical, acquisition, electrophysiology offerings

Vado Steerable Introducer Sheath image courtesy of Kalila Medical

News | Ablation Systems| February 02, 2016
Abbott announced that it has acquired private medical device company Kalila Medical Inc. Kalila Medical is a developer...
Allegheny General Hospital, MRI, patients with implantable cardiac devices, safety and effectiveness
News | EP Lab| February 01, 2016
The findings of a major study led by cardiovascular imaging specialists at Allegheny General Hospital (AGH) suggest...
News | EP Lab| January 29, 2016
Diseased hearts may be thrown out of rhythm by structural differences, now visible for the first time, in protein...
Technology | Ultrasound Intra-cardiac Echo (ICE)| January 26, 2016
Conavi Medical Inc. (formerly Colibri Technologies Inc.) has received U.S. Food and Drug Administration (FDA) 510(k)...
Kyoto University, Panasonic, remote heartbeat sensing, millimeter-wave radar

Japanese researchers have come up with a way to measure heartbeats remotely, in real time, and under controlled conditions with as much accuracy as electrocardiographs. The technology utilizes spread-spectrum radar to catch signals from the body and an algorithm that distinguishes heartbeats from other signals.

News | Remote Monitoring| January 26, 2016
Heartbeats can now be measured without placing sensors on the body, thanks to a new technology developed in Japan....
mechanical stimulation, cardiac cells, pacemakers, Technion-Israel Institute of Technology study
News | Pacemakers| January 26, 2016
January 26, 2016 — In a breakthrough that could change the future of...
St. Jude Medical, Optisure leads, FDA Class 1 Advisory, ICDs
News | Leads Implantable Devices| January 25, 2016
St. Jude Medical is recalling the Optisure implantable cardioverter defibrillator (ICD) leads due to a manufacturing...
Overlay Init